Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease

Overview

Journal Front Physiol

Date 2019 Apr 4

PMID 30941061

Citations 37

Authors

Siti Aishah Sulaiman

Nor I A Muhsin

Rahman Jamal

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) spectrum comprises simple steatosis and non-alcoholic steatohepatitis (NASH) that can lead to fibrosis and cirrhosis. The patients usually have no history of excessive alcohol consumption and other etiologies that can cause fatty liver. Understanding of the pathophysiology of NAFLD has revealed that non-coding RNAs (ncRNAs) play significant roles in modulating the disease susceptibility, pathogenesis and progression. Currently, the ncRNAs are grouped according to their sizes and their regulatory or housekeeping functions. Each of these ncRNAs has a wide range of involvement in the regulation of the genes and biological pathways. Here, we briefly review the current literature the regulatory ncRNAs in NAFLD pathogenesis and progression, mainly the microRNAs, long non-coding RNAs and circular RNAs. We also discuss the co-regulatory functions and interactions between these ncRNAs in modulating the disease pathogenesis. Elucidation of ncRNAs in NAFLD may facilitate the identification of early diagnostic biomarkers and development of therapeutic strategies for NAFLD.

Citing Articles

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.

Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model.

Matboli M, Abdelbaky I, Khaled A, Khaled R, Hamady S, Farid L Lipids Health Dis. 2024; 23(1):266.

PMID: 39182075 PMC: 11344433. DOI: 10.1186/s12944-024-02231-9.

The impact and role of identified long noncoding RNAs in nonalcoholic fatty liver disease: A narrative review.

Shi N, Sun K, Tang H, Mao J J Clin Lab Anal. 2023; 37(11-12):e24943.

PMID: 37435630 PMC: 10431402. DOI: 10.1002/jcla.24943.

Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review.

Sulaiman S, Dorairaj V, Adrus M Biomedicines. 2023; 11(1).

PMID: 36672614 PMC: 9855725. DOI: 10.3390/biomedicines11010106.

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies.

Gutierrez-Cuevas J, Lucano-Landeros S, Lopez-Cifuentes D, Santos A, Armendariz-Borunda J Cancers (Basel). 2023; 15(1).

PMID: 36612019 PMC: 9818030. DOI: 10.3390/cancers15010023.

References

Turchinovich A, Baranova A, Drapkina O, Tonevitsky A . Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol. 2018; 9:1256. PMC: 6158334. DOI: 10.3389/fphys.2018.01256. View

Rayner K, Suarez Y, Davalos A, Parathath S, Fitzgerald M, Tamehiro N . MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010; 328(5985):1570-3. PMC: 3114628. DOI: 10.1126/science.1189862. View

Xu Y, Zalzala M, Xu J, Li Y, Yin L, Zhang Y . A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism. Nat Commun. 2015; 6:7466. PMC: 4479415. DOI: 10.1038/ncomms8466. View

Yu F, Lu Z, Cai J, Huang K, Chen B, Li G . MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis. Cell Cycle. 2015; 14(24):3885-96. PMC: 4825734. DOI: 10.1080/15384101.2015.1120917. View

Zhang M, Chi X, Qu N, Wang C . Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis. Biochem Biophys Res Commun. 2018; 499(1):66-70. DOI: 10.1016/j.bbrc.2018.03.127. View

Liu X, Pan Q, Zhang R, Shen F, Yan S, Sun C . Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol. 2016; 22(44):9844-9852. PMC: 5124990. DOI: 10.3748/wjg.v22.i44.9844. View

Melo C, Drost J, Wijchers P, van de Werken H, de Wit E, Vrielink J . eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell. 2013; 49(3):524-35. DOI: 10.1016/j.molcel.2012.11.021. View

Ghareghani P, Shanaki M, Ahmadi S, Khoshdel A, Rezvan N, Meshkani R . Aerobic endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33 dependent autophagy induction in high fat diet fed mice. Obes Res Clin Pract. 2017; 12(Suppl 2):80-89. DOI: 10.1016/j.orcp.2017.01.004. View

Clarke J, Sharapova T, Lake A, Blomme E, Maher J, Cherrington N . Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. J Appl Toxicol. 2013; 34(6):726-32. PMC: 4004685. DOI: 10.1002/jat.2960. View

10.

Grimaldi B, Bellet M, Katada S, Astarita G, Hirayama J, Amin R . PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab. 2010; 12(5):509-20. PMC: 4103168. DOI: 10.1016/j.cmet.2010.10.005. View

11.

Guo X, He C, Wang Y, Sun C, Li G, Su Q . Circular RNA Profiling and Bioinformatic Modeling Identify Its Regulatory Role in Hepatic Steatosis. Biomed Res Int. 2017; 2017:5936171. PMC: 5499244. DOI: 10.1155/2017/5936171. View

12.

Yu F, Chen B, Dong P, Zheng J . HOTAIR Epigenetically Modulates PTEN Expression via MicroRNA-29b: A Novel Mechanism in Regulation of Liver Fibrosis. Mol Ther. 2017; 25(1):205-217. PMC: 5363197. DOI: 10.1016/j.ymthe.2016.10.015. View

13.

Salvoza N, Klinzing D, Gopez-Cervantes J, Baclig M . Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2016; 11(4):e0153497. PMC: 4831793. DOI: 10.1371/journal.pone.0153497. View

14.

Ibrahim S, Hirsova P, Gores G . Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut. 2018; 67(5):963-972. PMC: 5889737. DOI: 10.1136/gutjnl-2017-315691. View

15.

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

16.

Liu X, Liang Y, Song R, Yang G, Han J, Lan Y . Long non-coding RNA NEAT1-modulated abnormal lipolysis via ATGL drives hepatocellular carcinoma proliferation. Mol Cancer. 2018; 17(1):90. PMC: 5953401. DOI: 10.1186/s12943-018-0838-5. View

17.

Li P, Ruan X, Yang L, Kiesewetter K, Zhao Y, Luo H . A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab. 2015; 21(3):455-67. PMC: 4350020. DOI: 10.1016/j.cmet.2015.02.004. View

18.

Tan Y, Ge G, Pan T, Wen D, Gan J . A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One. 2014; 9(8):e105192. PMC: 4139327. DOI: 10.1371/journal.pone.0105192. View

19.

Davalos A, Goedeke L, Smibert P, Ramirez C, Warrier N, Andreo U . miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A. 2011; 108(22):9232-7. PMC: 3107310. DOI: 10.1073/pnas.1102281108. View

20.

Yu F, Lu Z, Chen B, Dong P, Zheng J . Identification of a Novel lincRNA-p21-miR-181b-PTEN Signaling Cascade in Liver Fibrosis. Mediators Inflamm. 2016; 2016:9856538. PMC: 5004029. DOI: 10.1155/2016/9856538. View